Celgene's quarterly revenue rises 23 pct
Jan 28 (Reuters) - U.S. biotechnology company Celgene Corp reported a 23 percent rise in quarterly revenue due to higher demand for its flagship multiple myeloma drug, Revlimid.
The company's revenue rose to $2.56 billion in the fourth quarter ended Dec. 31, from $2.09 billion a year earlier.
Net profit fell to $561 million, or 69 cents per share, from $613.9 million, or 74 cents per share.
(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)
